Unlock stock picks and a broker-level newsfeed that powers Wall Street.

OTC Markets OTCQB - Delayed Quote USD

Arch Biopartners Inc. (ACHFF)

Compare

1.2200

+0.0600

+(5.17%)

At close: April 2 at 1:15:20 PM EDT

No Tool

Measure

UNDO

Redo

All

Favorites

Text

Statistics

Technicals

Fibonacci

Markings

Lines

Annotation

Arrow

Line

Horizontal

Vertical

Rectangle

Trend Line

Measurement Line

Average Line

Callout

Channel

Check

Continuous

Crossline

Elliott Wave

Ellipse

Doodle

Fib Projection

Fib Arc

Fib Fan

Fib Time Zone

Focus

Gann Fan

Gartley

Heart

Pitchfork

Quadrant Lines

Ray

Regression Line

Fib Retracement

Star

Speed Resistance Arc

Speed Resistance Line

Time Cycle

Tirone Levels

Volume Profile

Cross

Loading Chart for ACHFF

Arch Biopartners Closes Non-Brokered Private Placement

Arch Biopartners Arranges Non-Brokered Private Placement

Arch Biopartners Announces Health Canada No Objection Letter (NOL) Granted for Investigator-Led Phase II PONTiAK Trial Using Cilastatin to Target Drug-Toxin-Related Acute Kidney Injury (AKI)

Shares for Interest Debt Settlement

Arch Biopartners Announces Ontario Research Ethics Board Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury (CS-AKI)

Arch Biopartners doses first subject in trial of acute kidney injury treatment

Arch Biopartners Announces Dosing of First Patient in Canada in the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Closes Units for Debt Settlement

Units for Debt Settlement

Arch Biopartners Announces Alberta Health Services Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury (CS-AKI)

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance